NASDAQ · CAMP
Healthcare · Biotechnology
$3.39
Up+$0.10 (+3.04%)
Updated Oct 23, 2026, 2:35 AM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CAMP
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 22, 2026
CAMP closed at $3.39 after 21 trading sessions, down 11.72% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 22, 2026 | $3.20 | $3.50 | $3.195 | $3.39 | 141.13K |
| Oct 21, 2026 | $3.17 | $3.33 | $2.96 | $3.29 | 186.41K |
| Oct 20, 2026 | $3.18 | $3.38 | $3.11 | $3.16 | 89.17K |
| Oct 19, 2026 | $3.20 | $3.41 | $3.11 | $3.14 | 57.71K |
| Oct 16, 2026 | $3.45 | $3.45 | $3.17 | $3.17 | 92.42K |
| Oct 15, 2026 | $3.46 | $3.54 | $3.43 | $3.45 | 56.26K |
| Oct 14, 2026 | $3.33 | $3.445 | $3.17 | $3.43 | 155.72K |
| Oct 13, 2026 | $3.66 | $3.7995 | $3.38 | $3.43 | 88.47K |
| Oct 12, 2026 | $3.71 | $3.76 | $3.65 | $3.66 | 36.06K |
| Oct 9, 2026 | $3.70 | $3.87 | $3.62 | $3.77 | 72.15K |
| Oct 8, 2026 | $3.80 | $3.80 | $3.51 | $3.70 | 278.33K |
| Oct 7, 2026 | $3.85 | $4.12 | $3.84 | $3.84 | 148.5K |
| Oct 6, 2026 | $4.03 | $4.03 | $3.75 | $3.96 | 1.23M |
| Oct 5, 2026 | $4.00 | $4.09 | $3.74 | $4.01 | 381.16K |
| Oct 2, 2026 | $3.90 | $4.05 | $3.69 | $4.00 | 367.96K |
| Oct 1, 2026 | $3.99 | $4.1517 | $3.76 | $3.84 | 994.72K |
| Sep 30, 2026 | $3.96 | $4.09 | $3.86 | $4.04 | 170.66K |
| Sep 29, 2026 | $3.87 | $4.02 | $3.81 | $3.91 | 172.54K |
| Sep 28, 2026 | $3.86 | $3.95 | $3.73 | $3.85 | 116.91K |
| Sep 25, 2026 | $3.83 | $4.06 | $3.724 | $3.92 | 477.4K |
| Sep 24, 2026 | $3.78 | $3.94 | $3.675 | $3.84 | 130.35K |
The latest Smart Investors Daily articles mentioning CAMP.
Company
Market Activity
Research & News
CAMP research
Company profile and research snapshot.
Camp4 Therapeutics Corp is a clinical stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 15, 2026 | Needham | Buy | — |
| Oct 5, 2026 | Oppenheimer | Outperform | — |
| Sep 29, 2026 | Chardan Capital | Buy | — |
| Aug 14, 2026 | Piper Sandler | Overweight | — |
| Jun 16, 2026 | JP Morgan | Overweight | — |
Generated Oct 22, 2026, 9:13 PM
CAMP4 Therapeutics gained 3.04% today as the biotech company showcased its RNA-based therapeutic platform at an industry conference. The positive momentum reflects investor optimism around the company's pipeline programs targeting genetic diseases through innovative RNA repair mechanisms.
Bottom line: CAMP4's modest 3% gain reflects positive sentiment around its RNA therapeutics platform and sector tailwinds rather than company-specific catalysts. Investors should monitor upcoming clinical trial data and pipeline advancement as key catalysts, while remaining mindful of the significant execution risks inherent in early-stage genetic disease therapeutics development.
Yahoo · Oct 20, 2026
Korro and Tevard outlined approaches designed to expand the therapeutic use of RNA medicines beyond protein silencing, highlighting programs that aim to repair genetic defects or restore production of full-length proteins. Speaking during a Chardan panel on RNA medicines, Ram Aiyar, CEO and preside
Benzinga · Oct 15, 2026
Needham analyst Joseph Stringer initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Buy rating and announces Price Target of $8.
Yahoo · Oct 14, 2026
WATERTOWN, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that the company will participate in a panel during Chardan’s 10th Annual Healthcare Conference on October 20, 2026. Details below: Char
Benzinga · Sep 29, 2026
Chardan Capital analyst Keay Nakae maintains Camp4 Therapeutics (NASDAQ:CAMP) with a Buy and lowers the price target from $6.5 to $6.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CAMP.
